Log In
BCIQ
Print this Print this
 

VDA-1102 IV

  Manage Alerts
Collapse Summary General Information
Company Vidac Pharma Ltd.
DescriptionAnti-neoplastic agent with selective modulation of VDAC/HK2 to trigger apoptosis in cancer cells
Molecular Target Voltage-dependent anion channel 2 (VDAC2) ; Hexokinase 2 (HK2)
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPreclinical
Standard IndicationSolid tumors
Indication DetailsTreat solid tumors
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today